Array BioPharma, Inc. (ARRY) recently presented data on ARRY-520 from two ongoing studies in multiple myeloma.
In 2012, Array BioPharma made progress on its proprietary programs ARRY-614 (indicated for myelodysplastic syndromes) and ARRY-520 (indicated for MM). Array BioPharma wants to invest its resources in the hematology/oncology segment, in which it sees great opportunities. This year, Array BioPharma expects to generate more data for registration of study decisions of the two programs.
Single agent activity was demonstrated by ARRY-520 in pretreated patients – median overall survival and overall response rate was 19 months and 16%, respectively.
In the study, ARRY-520 was well tolerated. Predominant adverse events like transient and non-cumulative neutropenia and thrombocytopenia were manageable. There was a low-incidence of non-hematologic adverse events and no-treatment related neuropathy was observed.
In the second study, ARRY-520 was evaluated in combination with Takeda Pharmaceutical’s (TKPYY) Velcade (bortezomib). The combination was well-tolerated. The most common adverse event was neutropenia.
Initial response and prolonged stable disease was observed in the patient population, most of whom had not benefitted from Velcade treatment. The study will also evaluate an alternate treatment regimen with the addition of low-dose dexamethasone.
We note companies like Onyx Pharmaceuticals, Inc. (ONXX) have a presence in the multiple myeloma market. Onyx Pharmaceuticals’ Kyprolis (carfilzomib) is indicated for the treatment of multiple myeloma patients who have received at least two prior therapies including Velcade and an immunomodulatory agent, and whose disease has progressed on or within 60 days of completion of the last therapy.
Currently, Array BioPharma carries a Zacks Rank #3 (Hold). However, companies like GTX Inc. (GTXI) look better positioned with a Zacks Rank #2 (Buy).
More From Zacks.com